Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the retrospective trial (RRP-002) maintained... Read More

PLYMOUTH MEETING, Pa. , Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board of... Read More

New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries... Read More

New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data supporting mechanism of action... Read More

PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference ( Edinburgh, UK ; November 12-15 ) Presentation and poster... Read More

PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024 . Following the release, INOVIO will host a live... Read More

American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy: New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma International Society of Vaccines Conference: Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent... Read More

PLYMOUTH MEETING, Pa. , Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board of Directors... Read More

PLYMOUTH MEETING, Pa. , Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew... Read More

PLYMOUTH MEETING, Pa. , Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith , VP of Preclinical R&D at INOVIO... Read More

PLYMOUTH MEETING, Pa. , Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments. "We continue to make progress with our lead candidate,... Read More

PLYMOUTH MEETING, Pa. , Aug. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board of... Read More

Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization Application PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Medicines Agency's Committee for... Read More

PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2024 financial results will be released after the market close on August 8, 2024 . Following the release, INOVIO will host a live conference... Read More

Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP) PLYMOUTH MEETING, Pa. , July 11, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today... Read More

Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa. , July 2, 2024 /PRNewswire/ -- INOVIO... Read More

PLYMOUTH MEETING, Pa. , July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board of... Read More

PLYMOUTH MEETING, Pa. , July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced its inclusion in the Russell 2000 ® Index as part of the annual reconstitution of the Russell stock indexes. This reconstitution became effective after the close... Read More

PLYMOUTH MEETING, Pa. , June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea , and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan... Read More

PLYMOUTH MEETING, Pa. , May 31, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board of... Read More

BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) Planning initiation of confirmatory trial for INO-3107 based on FDA feedback Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZI TM (toripalimab-tpzi) as a potential treatment for oropharyngeal squamous cell... Read More

PLYMOUTH MEETING, Pa. , May 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board of... Read More

PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May: The Citizens JMP Life Sciences Conference Date: Tuesday, May 14,... Read More

PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024 . Following the release, INOVIO will host a live conference... Read More

PLYMOUTH MEETING, Pa. , April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. ( Nasdaq : INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded... Read More

PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea , President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2,... Read More

Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP) Positive data announced from Phase 1/2 trial Orphan Drug Designation granted by European Union Breakthrough Therapy Designation granted by U.S. Food and Drug Administration (FDA) Received FDA feedback that data from completed Phase 1/2 trial can be used to submit Biological License Application... Read More

PHILADELPHIA , March 6, 2024 /PRNewswire/ -- Geneos Therapeutics , a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b /2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, at the 2024... Read More

PLYMOUTH MEETING, Pa. , Feb. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter and year-end 2023 financial results will be released after the market close on March 6, 2024 . Following the release, INOVIO will host a live... Read More

PLYMOUTH MEETING, Pa. , Feb. 7, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea , President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Oppenheimer 34th Annual Healthcare Life... Read More

PLYMOUTH MEETING, Pa. , Feb. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board of... Read More

PLYMOUTH MEETING, Pa. , Jan. 23, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Wednesday , January 24, 2024. The... Read More

Fireside Chat, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, January 24, 2024, at 12:00pm ET PLYMOUTH MEETING, Pa. , Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual... Read More

Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer PLYMOUTH MEETING, Pa. and REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today... Read More

Company will request Rolling Submission and Priority Review of its Biological License Application (BLA) by U.S. Food and Drug Administration (FDA) to expedite review process Accelerating commercialization efforts to be prepared to launch INO-3107 in 2025 PLYMOUTH MEETING, Pa. , Jan. 3, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and... Read More

Achieved significant progress with lead product candidate, INO-3107 Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) Received FDA feedback that data from completed Phase 1/2 trial could be used to submit a Biological License Application (BLA) under Accelerated Approval program Accelerating commercialization strategy... Read More

PLYMOUTH MEETING, Pa. , Nov. 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board of... Read More

PLYMOUTH MEETING, Pa. , Oct. 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2023 financial results will be released after the market close on November 9, 2023 . Following the release, INOVIO will host a live... Read More

Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission If approved, INO-3107 could potentially revolutionize treatment options for patients with Recurrent Respiratory Papillomatosis (RRP), a debilitating rare disease caused by human papillomavirus (HPV) INO-3107 could be the first DNA medicine available in the United States and the first commercial product for INOVIO... Read More

Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer Shanghai -based SHC Added to Geneos' Investor Syndicate PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- Geneos Therapeutics , a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has completed its Series A3 financing round... Read More

Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies First Breakthrough Therapy designation for an INOVIO DNA medicine candidate PLYMOUTH MEETING, Pa. , Sept. 7, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and... Read More

PLYMOUTH MEETING, Pa. , Aug. 29, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea , President and CEO will present at the H.C. Wainwright 25th Annual Global Investment Conference. H.C. Wainwright 25th Annual Global... Read More

Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates closest to market and with greatest opportunity to deliver on the promise of DNA medicines for patients Following biomarker... Read More

PLYMOUTH MEETING, Pa. , Aug. 4, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board... Read More

PLYMOUTH MEETING, Pa. , July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2023 financial results will be released after the market close on August 9, 2023 . Following the release, INOVIO will host a live conference... Read More

Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA: UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 2:20-cv-01962-GJP NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTIONS TO:... Read More

PLYMOUTH MEETING, Pa. , June 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board... Read More

PLYMOUTH MEETING, Pa. , May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea , President and CEO, and Dr. Michael Sumner , CMO, will present at the 2023 Jefferies Healthcare Conference. 2023 Jefferies Healthcare... Read More

PLYMOUTH MEETING, Pa. , May 23, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company's product candidate for the treatment of Recurrent Respiratory... Read More

Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatment New combined safety and immunological data showing tolerability and durable immune response presented at ABEA/COSM Announced positive data from Phase 1b trial with... Read More

Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and has the potential to provide clinical benefit to adults with RRP PLYMOUTH MEETING, Pa. , May 8, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from... Read More

PLYMOUTH MEETING, Pa. , May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea , Ph.D., President and CEO, will present at the 2023 RBC Capital Markets Global Healthcare Conference. 2023 RBC Capital Markets Global... Read More

PLYMOUTH MEETING, Pa. , April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023 . Following the release, INOVIO will host a live conference... Read More

Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5 th PLYMOUTH MEETING, Pa. , April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for... Read More

European Commission to review and make a final decision, expected late May 2023 PLYMOUTH MEETING, Pa. , April 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Committee for Orphan Medicinal Products (COMP) has provided a... Read More

Oral presentation introduced new humoral and cellular response data indicating potential ability of INO-4201 to generate robust immune response and protect against Zaire ebolavirus PLYMOUTH MEETING, Pa. , April 17, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious... Read More

Immunological data from recently completed Phase 1b trial will be presented on April 16 th PLYMOUTH MEETING, Pa. , April 12, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for presentation for INO-4201 as... Read More

PLYMOUTH MEETING, Pa. , April 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to its newly hired Senior Vice President, Regulatory Affairs under its 2022 Inducement Plan (the "Inducement Plan"). The... Read More

PLYMOUTH MEETING, Pa. , March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea , Ph.D., President and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference. Oppenheimer 33rd Annual Healthcare Conference... Read More

Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) Trial results did not meet the primary endpoint in the biomarker-selected population Trial results did achieve statistical significance in the all-participants population Highlights progress of promising product candidates: Positive preliminary data from Phase 1/2... Read More

10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgery Treatment with INO-3107 achieved statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous year INO-3107 was well-tolerated and immunogenic, with efficacy and safety... Read More

PLYMOUTH MEETING, Pa. , Feb. 15, 2023 /PRNewswire/ -- INOVIO ( NASDAQ : INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter 2022 financial results will be released after the market close on March 1, 2023 . Following the release, INOVIO will host a live... Read More

PLYMOUTH MEETING, Pa. , Feb. 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). On February 2 nd , 2023 (the "Grant Date"), the... Read More

INO-4201 found to be well-tolerated in the trial Humoral responses were boosted in 100% (36 of 36) of treated participants PLYMOUTH MEETING, Pa. , Feb. 2, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced positive results from a Phase 1b... Read More

Cost-saving measures include 11% headcount reduction Annual savings expected to be approximately $4.3 million Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RRP and VGX-3100 for cervical HSIL PLYMOUTH MEETING, Pa. , Jan. 31, 2023 /PRNewswire/ -- INOVIO ( NASDAQ : INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people... Read More